We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we live, learn and work.

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works. Those headwinds included the difficulties it faced in ...

Novavax (NASDAQ:NVAX) said that it has officially transferred the marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi (NASDAQ:SNY) within the European Union. As a result of this ...

Moderna is producing its first made-in-Canada COVID-19 shots at facilities in Laval, Que. and Cambridge, Ont. The Laval ...

Novavax's $500M Sanofi partnership with a potential $700M in milestones provides stability as the company transitions to a partnership-focused strategy. Health Secretary Kennedy's claim that ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Novavax reported Q4 sales of $88.31 million. EPS loss was $0.51, matching Wall Street estimates. Novavax expects $300-$350 million in adjusted revenue for 2025. This simple system has nailed 1,000+ ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...